phrykt

Integra Lifesciences Holdings Corp (IART): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of IART were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Integra Lifesciences Holdings

From the latest filings

Overall: more buying than selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IART

211 funds and institutions reported IART shares worth $1.3B at the end of Q2 2026, about 96% of the company. The largest holder is BlackRock, Inc. with 13.7%.

Funds and institutions (13F) 96%Everyone else 4%

10 largest owners, by share of the company

BlackRock, Inc.13.7%
Rubric Capital Management LP10.0%
Invesco Ltd.4.8%
Vanguard Portfolio Management LLC4.8%
Morgan Stanley4.6%
Paradigm Capital Management Inc4.4%
Fuller & Thaler Asset Management, Inc.4.4%
State Street Corp3.8%
Vanguard Capital Management LLC3.8%
Neuberger Berman Group LLC3.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.10.68M13.73%$192M+4%
Rubric Capital Management LP7.75M9.97%$139MNo change
Invesco Ltd.3.75M4.82%$67.3M+8%
Vanguard Portfolio Management LLC3.74M4.81%$67.2M+2%
Morgan Stanley3.59M4.62%$64.5M+0%
Paradigm Capital Management Inc3.44M4.42%$61.8M-14%
Fuller & Thaler Asset Management, Inc.3.44M4.42%$61.7M-3%
State Street Corp2.95M3.79%$52.9M+2%
Vanguard Capital Management LLC2.95M3.79%$52.9M+2%
Neuberger Berman Group LLC2.36M3.04%$42.6M+12%
Dimensional Fund Advisors LP2.22M2.85%$39.8M-20%
Geode Capital Management, LLC1.79M2.30%$32.2M+8%
Goldman Sachs Group Inc1.47M1.89%$26.5M-21%
Wellington Management Group LLP1.46M1.88%$26.2M+12%
Millennium Management LLC1.44M1.85%$25.9M+131%
Charles Schwab Investment Management Inc1.40M1.80%$25.2M-13%
Sixth Street Partners Management Company, L.P.1.40M1.80%$25.2M–
Bank of America Corp1.33M1.71%$23.9M-6%
Systematic Financial Management LP1.02M1.32%$18.4M-3%
Allianz Asset Management GmbH1.01M1.29%$18.1M+13%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No IART insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IART short interest

High short interest. 10.1% of IART shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 14%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 7.90M IART shares were sold short, 10.1% of the shares outstanding, up 7.9% from the report before. At the average daily volume of 1.24M shares, buying them all back would take about 6.4 trading days (days to cover).

Shares short, % of all shares

10.1%May 15Oct 3012.4%

Days to cover

6.4May 15Oct 3013.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20267.90M10.15%+8%1.24M6.4
Oct 15, 20267.32M9.41%+1%1.33M5.5
Sep 30, 20267.27M9.34%+7%967,9477.5
Sep 15, 20266.81M8.75%-1%823,9848.3
Aug 31, 20266.86M8.82%+2%557,30412.3
Aug 14, 20266.74M8.67%+4%677,6159.9
Jul 31, 20266.48M8.33%+4%1.11M5.8
Jul 15, 20266.21M7.98%-3%865,0847.2
Jun 30, 20266.39M8.22%-11%1.12M5.7
Jun 15, 20267.22M9.28%-10%833,9118.7
May 29, 20267.99M10.26%-13%988,5028.1
May 15, 20269.20M11.83%-1%1.51M6.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Integra Lifesciences Holdings company events

Integra Lifesciences Holdings filed 12 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 21, 2026.

  1. Oct 21, 2026ResultsReleased financial results. Filing
  2. Oct 19, 2026AgreementIntegra LifeSciences Holdings Corporation entered into an amended and restated credit agreement with a syndicate of lending banks, and Bank of America, N.A., as Administrative Agent, Swing Line Lender and a L/C Issuer. Filing
  3. Oct 9, 2026AnnouncementShared information with investors. Filing
  4. Oct 2, 2026ResultsReleased financial results. Filing
  5. Sep 8, 2026AnnouncementShared information with investors. Filing
  6. Jul 29, 2026ResultsReleased financial results. Filing
  7. May 8, 2026LeadershipIntegra LifeSciences Holdings Corporation held its 2026 Annual Meeting of Stockholders on May 7, 2026. Filing
  8. May 5, 2026LeadershipIntegra LifeSciences Holdings Corporation announced the appointment of Dr. Stuart M. Essig to serve as its President and Chief Executive Officer, effective as of May 1, 2026. Filing
  9. May 5, 2026ResultsReleased financial results. Filing
  10. Apr 15, 2026AgreementAs previously disclosed, on December 18, 2018, certain subsidiaries of Integra LifeSciences Holdings Corporation, a Delaware corporation, entered into a $150 million accounts receivable securitization facility to reduce outstanding revolving borrowings under the Company’s senior credit facility and… Filing
  11. Feb 26, 2026ResultsReleased financial results. Filing
  12. Dec 12, 2025LeadershipIntegra LifeSciences Holdings Corporation adopted a change in control severance program under which certain executives of the Company, including Lea Knight, Executive Vice President and Chief Financial Officer, Robert T. Davis, Jr., Executive Vice President, President – Tissue Technologies, Michael… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Integra Lifesciences Holdings financials

Famous investors that hold IART

3 of the 50 well-known investors we track reported holding IART in their latest 13F filing. The largest position is Ken Griffin's, worth $8.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026544,167$8.9M0.0%New
Israel Englander · Millennium ManagementQ3 2026430,391$7M0.0%-70%
Paul Tudor Jones · Tudor Investment CorpQ3 2026108,684$1.8M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IART in the last 120 days.

FiledHolderFormStake
Nov 10, 2026Invesco Ltd.13G5.4%
Nov 10, 2026Invesco Ltd.13G5.4%

Questions about Integra Lifesciences Holdings Corp (IART) stock

Who owns the most IART stock?

The largest reported owner of Integra Lifesciences Holdings Corp (IART) is BlackRock, Inc., with 13.7% of the company. In total, 211 funds and institutions reported holding IART at the end of Q2 2026, together about 96% of the shares. See the largest owners.

Are IART insiders buying or selling?

No IART insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in IART?

As of Oct 30, 2026, 7.90M IART shares were sold short, 10.1% of the shares outstanding, up 7.9% from the report before. At the average daily volume of 1.24M shares, buying them all back would take about 6.4 trading days (days to cover). See the history.

Which famous investors hold IART?

3 of the 50 well-known investors we track reported IART in their latest 13F filing, including Ken Griffin, Israel Englander, Paul Tudor Jones. The largest position is worth $8.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.